Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug your doctor prescribed.

Wegovy and Ozempic remain on the FDA's shortages list, despite strenuous efforts ... professionals turning to unapproved versions of GLP-1 drugs as an option for weight loss, saying: "This can ...

While Victoza sales are falling as patients switch to newer, once-weekly drugs ... shortages list, mainly due to pressures on Novo Nordisk's production capacity for its entire GLP-1 franchise ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Cencora simplifies distribution logistics by shipping products to centralized wholesaler locations, as opposed to shipping directly to pharmacies and various customer locations. Additionally, Cencora ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

The Medicines and Healthcare Products Regulatory Agency (MHRA) has ruled that warnings about the risk should now be added to ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Bloomfield-based Cigna announced this week a new initiative that aims to reduce out-of-pocket prescription-drug costs and make those costs more transparent.

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.